Overview
- CEO John Rim said the Rockville, Maryland acquisition from GSK for about $280 million is slated to close in March, bringing 60,000 liters of capacity online in the United States.
- Samsung Biologics plans to upgrade the Rockville site with an additional 20,000 to 40,000 liters and will initially continue manufacturing GSK products, including Benlysta.
- Rim said the company will initiate construction of a sixth plant in 2026 and has secured land for a new Songdo campus, with current global capacity reported at 845,000 liters.
- The growth plan centers on scaling capacity, broadening CRO, CDO and CMO offerings, and strengthening U.S. production and sales to meet customer demand for local supply.
- Management cited ample cash and low leverage, said no decision has been made on issuing bonds, and outlined roughly 7 trillion won in investments through 2034.